Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents
Romy Hurwitz, Roger Blackmore, Philip Hazell, Katrina Williams, Susan Woolfenden
Cochrane Database of Systematic Reviews | WILEY | Published : 2012
Philip Hazell - has worked as a consultant for Eli Lilly and Janssen. He has research contracts with Eli Lilly and Celltech. He is a member of the advisory board of Eli Lilly, Australia; Janssen, Australia; Novartis, Australia and Shire, International. Dr Hazell has given presentations for Eli Lilly, Pfizer, Janssen and Sanofi. He is an investigator in a trial of fluoxetine for autism spectrum disorders.